You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.
Study subjects of both sexes who had low germline mutation rates lived nearly five years longer than individuals with high mutation rates.
Launched in 2016 by researchers in Utah, the firm recently published a genome-wide signature that predicts survival of glioblastoma patients.
Nature News reports that some geneticists are concerned that they only learned from a colleague's tweet that they might have been exposed to SARS-CoV-2.
The Deseret News reports that a rapid DNA sequencing project to diagnose sick infants has begun in Utah.
In Science this week: comprehensive cellular map of the human thymus, evidence of admixture between the ancestors of Neanderthals and Denisovan and a 'superarchaic' population.
This superarchaic hominin population split from other humans about 2 million years ago and interbred with the ancestors of Neanderthals and Denisovans about 700,000 years ago.
In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.
The All of Us program aims to enroll 1 million Americans willing to donate biological samples and share a variety of genetic and health data.
Having a distant relative with Alzheimer's disease may increase an individual's risk of developing the according to the Telegraph.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.